Nadim Ahmed has over twenty-five years of leadership experience in oncology development and commercialization. In his current role as CEO of Cullinan Oncology, Nadim oversees an expert team focused on creating new standards of care for patients with cancer through a modality-agnostic, targeted oncology approach to building a diversified pipeline of first-in-class and best-in-class therapeutics.

Previously, at Bristol Myers Squibb, he served as President, Hematology and at Celgene Corporation where he served as President, Global Hematology & Oncology through its acquisition by BMS. As President, Hematology at BMS, Nadim oversaw multiple product launches and participated as a member of the company’s Leadership Team.

Prior to BMS, Nadim served in leadership roles at Celgene across multiple disciplines. During this time, he successfully launched several cancer medicines, including Pomalyst®, Abraxane® and key indications for Revlimid®. Nadim has worked with various treatment modalities, including small molecules, biologics and cell therapy.

He holds a Master of Science degree from Loughborough University, UK and a Bachelor of Science degree from University College London, UK. Nadim currently serves on the Board of Directors for Family Promise, a national non-profit organization helping families impacted by homelessness.